Quoin Pharmaceuticals Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
57.0%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$6.88next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Q4 and Full Year 2026 Earnings Release | 18 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash Runway (Months) Quarterly8.4Target: 12.0+
QRX003 Phase 3 Trial Enrollment Rate QuarterlyTarget: 100% enrollment by end of 2026
Quarterly Net Loss (USD Millions) Quarterly5.0
Watch Items
- QRX003 Phase 3 Topline Data ReleaseTrigger: H2 2026Action: Evaluate clinical efficacy (Investigator's Global Assessment improvement) and safety profile to assess NDA filing viability.
- Cash Position and Capital RaisingTrigger: < $10.0 MillionAction: Assess potential dilution from warrant exercises or new equity/debt financing to extend runway into 2027.
- QRX009 Proof of Concept InitiationTrigger: H2 2026Action: Monitor the start of clinical testing for the topical rapamycin program in at least one orphan indication.
Research as of 20 Jun 2026